As of May 2025, the case remains pending in New Jersey state court
Applying inclusion and exclusion criteria for the selection of relevant articles, reaching the conclusion that the long-term use of semaglutide produces effects on body weight and modification of cardiovascular risk factors, which is associated with a reduction in the premature mortality rate and improvement of the complications associated with having an elevated body mass index
The reported side-effect profile matches semaglutide broadly: nausea, GI upset, fatigue, and headache during titration, usually easing over the first 48 weeks
Metabolic profiling provided no evidence for changes in locomotor activity, lower food intake or water intake, or changes in energy expenditure or respiratory exchange ratio (Supplemental Figure 4, EI) between lean WT and Tmprss2 / mice
Medications can lose their effectiveness over time, and using expired tirzepatide could impact your treatment outcomes